tiprankstipranks
Advertisement
Advertisement

ABBV Stock Latest News

Citizens biotechnology analyst holds analyst/industry conference call
The FlyCitizens biotechnology analyst holds analyst/industry conference call
1d ago
AZ
GSK
AbbVie’s ABBV-438 Myeloma Trial: Early-Stage Bet on Long-Term Oncology Growth
PremiumCompany Announcements
AbbVie’s ABBV-438 Myeloma Trial: Early-Stage Bet on Long-Term Oncology Growth
2d ago
ABBV
AbbVie price target lowered to $232 from $233 at Evercore ISI
PremiumThe Fly
AbbVie price target lowered to $232 from $233 at Evercore ISI
3d ago
ABBV
CollPlant announces termination of development agreement with AbbVie
PremiumThe Fly
CollPlant announces termination of development agreement with AbbVie
3d ago
ABBV
CLGN
AbbVie announces results from Phase 2 IMGN853-0420 trial
PremiumThe Fly
AbbVie announces results from Phase 2 IMGN853-0420 trial
3d ago
ABBV
The Week That Was, The Week Ahead: Macro and Markets, April 12
PremiumMarket NewsThe Week That Was, The Week Ahead: Macro and Markets, April 12
4d ago
C
GS
AbbVie Stock Forecast: Trending Buy Calls From Analysts
Premium
Analysts
AbbVie Stock Forecast: Trending Buy Calls From Analysts
5d ago
ABBV
AbbVie Stock Forecast: Trending Moderate Buy Among Analysts
Premium
Analysts
AbbVie Stock Forecast: Trending Moderate Buy Among Analysts
6d ago
ABBV
AbbVie price target raised to $249 from $242 at Guggenheim
PremiumThe Fly
AbbVie price target raised to $249 from $242 at Guggenheim
6d ago
ABBV
Trump Trade: AbbVie sues White House over discount drug program
PremiumThe Fly
Trump Trade: AbbVie sues White House over discount drug program
7d ago
NNE
SPY
Three Options Trades That Could Return Up To 841%
PremiumMarket News
Three Options Trades That Could Return Up To 841%
7d ago
DIS
UNH
AbbVie sues White House over discount drug program, Axios says
PremiumThe Fly
AbbVie sues White House over discount drug program, Axios says
8d ago
ABBV
AbbVie price target lowered to $240 from $250 at Cantor Fitzgerald
PremiumThe FlyAbbVie price target lowered to $240 from $250 at Cantor Fitzgerald
8d ago
ABBV
AbbVie’s Real‑World Parkinson’s Study in Belgium: What Investors Should Watch
Premium
Company Announcements
AbbVie’s Real‑World Parkinson’s Study in Belgium: What Investors Should Watch
8d ago
ABBV
AbbVie should be bought on recent selloff, says JPMorgan
Premium
The Fly
AbbVie should be bought on recent selloff, says JPMorgan
9d ago
ABBV
AbbVie, Genentech to sell popular commercial drugs on TrumpRx, CBS says
PremiumThe Fly
AbbVie, Genentech to sell popular commercial drugs on TrumpRx, CBS says
9d ago
ABBV
CHRO
Oruka Therapeutics price target raised to $125 from $60 at Guggenheim
PremiumThe Fly
Oruka Therapeutics price target raised to $125 from $60 at Guggenheim
10d ago
ABBV
ORKA
AbbVie’s Real-World Migraine Study Nears Data Release: What Investors Should Watch
PremiumCompany Announcements
AbbVie’s Real-World Migraine Study Nears Data Release: What Investors Should Watch
13d ago
ABBV
AbbVie: Resilient Core, Growing Aesthetics, and Strategic Acquisitions Underpin Buy Rating
PremiumRatings
AbbVie: Resilient Core, Growing Aesthetics, and Strategic Acquisitions Underpin Buy Rating
15d ago
ABBV
AbbVie: Immunology Strength, Strategic Acquisitions, and Patent Headwind Execution Support Buy Rating
PremiumRatingsAbbVie: Immunology Strength, Strategic Acquisitions, and Patent Headwind Execution Support Buy Rating
17d ago
ABBV
AbbVie call volume above normal and directionally bullish
Premium
The Fly
AbbVie call volume above normal and directionally bullish
19d ago
ABBV
AbbVie’s Global IBD Outcomes Study: What Treat-to-Target Data Could Mean for Investors
Premium
Company Announcements
AbbVie’s Global IBD Outcomes Study: What Treat-to-Target Data Could Mean for Investors
19d ago
ABBV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >